A pivotal Alzheimer’s trial tied to Vivek Ramaswamy’s political rise is a tale of failed endpoints.

A program that’s survived Vir’s pivot away from infectious disease research hit all of its study objectives and appeared more ...

Regulators finalized a rule Wednesday that would slash payments for drugs in the controversial 340B program and equalize some ...

AstraZeneca will “redeploy resources” through a new restructuring program. Meanwhile, Alnylam shares sold off on fears ...

The latest installment in BioPharma Dive’s visualization-focused series features a look at investors’ response to a trio of ...

J&J and AbbVie are among the companies advancing “trispecific” antibodies that could become another step forward in treatment ...

The occurrence of cancer in nine recipients — two of which involved evidence that a viral delivery tool integrated into ...

The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier ...

On a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall ...

Historical data suggests the sector outperforms after midterm elections. And Democrats, newly in control of Congress, have ...

Wall Street analysts are already resetting projections for Rasonque — but company executives cautioned that it’s too early to ...

The San Diego biotechnology startup is one of several firms working on a cutting-edge technique with the potential to slow or ...